Last reviewed · How we verify
NCT07067723
Epidemiological and Clinical Characteristics of Human Mpox Outbreak in Equateur Province in the Democratic Republic of Congo (Part2)
trial in Monkeypox (Mpox) in 122 participants. Enrolling by invitation.
31 December 2025
Quick facts
| Lead sponsor | Osaka Metropolitan University |
|---|---|
| Status | ENROLLING BY INVITATION |
| Study type | OBSERVATIONAL |
| Enrollment | 122 |
| Start date | 1 August 2024 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across Democratic Republic of the Congo |
Conditions studied
- Monkeypox (Mpox) — all drugs for Monkeypox (Mpox) →
Sponsor
Osaka Metropolitan University
Who can join
Eligibility, any sex, with Monkeypox (Mpox). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is * to better understand the dominant modes of transmission * to estimate the extent of transmission among contacts by determining the secondary infection rate for human-to-human transmission at an individual level and identifying factors associated with secondary infections. * to determine the proportion of asymptomatic or pauci-symptomatic infections. * to characterize the incubation period of mpox and the duration of infectiousness, including reproduction numbers. * to assess serological responses following confirmed infection.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07067723
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Monkeypox (Mpox)
Currently open trials in the same condition.
- NCT07199569 — Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells · Phase 2 · active not recruiting
- NCT06840860 — Epidemiological and Pathophysiological Insights Through a Cross-sectional Survey (EPIC) · recruiting
- NCT06549530 — Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children From 2 Years to Less Than 12 Years · Phase 2 · active not recruiting
Other Osaka Metropolitan University trials
Trials by the same sponsor.
- NCT06984705 — Epidemiological and Clinical Characteristics of Human Mpox Outbreak in Equateur Province in the Democratic Republic of C · enrolling by invitation
- NCT06694012 — Osaka Cardiometabolic Epidemiological Study: Ohtori Study Part 2 · recruiting
- NCT07055867 — Epidemiological and Clinical Characteristics of Mpox Outbreak in Equateur, the DR Congo (Part1) · enrolling by invitation
- NCT06432543 — Polyethylene Wear Particle Analysis of THA · recruiting
- NCT06426641 — Polyethylene Wear Particle Analysis of TKA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07067723 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Osaka Metropolitan University
- Last refreshed: 16 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07067723.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing